Koru Medical announces novel therapies collaboration in late-stage endocrinology

KORU Medical “announced an agreement with a biopharmaceutical company to validate its FREEDOM(TM) Infusion System for use with the biopharma company’s drug, a novel biologic. Under terms of the Agreement, Koru Medical will validate the Freedom Infusion System for use with the company’s drug. The drug developer is expected to begin Phase III studies by the end of 2023 for treatment of a rare genetic disease with global prevalence of roughly 10,000 that currently has no pharmaceutical treatments.”